Compare Ascendis Pharma A/S (ASND) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Citius Pharmaceuticals Inc — how do they compare? Ascendis Pharma A/S trades at $246.23 (market cap $16.71B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $21.25M). The key difference: Ascendis Pharma A/S is far larger — about 786.4× Citius Pharmaceuticals Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ASND | CTXR | |
|---|---|---|
Market Cap | $16.71B | $21.25M |
Sector | Health | Health |
52-Week High | $277.18 | $1.82 |
52-Week Low | $189.74 | $0.48 |
Enterprise Value | $17.08B | $17.47M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, up 0.35% on the day, with a bullish technical outlook and strong analyst support. Recent Q2 2026 earnings beat expectations with EPS of $3.29 versus $1.71 expected, driven by robust product revenue growth of 105% year-over-year. The company shows improving financials, with net cash flow turning positive in 2025 and revenue projected to reach $866 million in 2026. Institutional sentiment is highly positive, with 92% of analysts rating the stock a buy.
The outlook for ASND is optimistic, supported by accelerating revenue growth, multiple product launches, and a path to profitability. Key risks include high debt levels, ongoing net losses, and competitive pressures in rare disease markets. The consensus price target of $309.75 implies significant upside, but investors should monitor execution on profitability goals and regulatory developments.
CTXR trades at $0.765, up 6.25% today, with a bullish technical signal from moving averages. The company reported a net income margin of -823.34% for 2025 and missed EPS estimates in recent quarters. Recent news highlights strong commercial momentum for LYMPHIR, with Q2 2026 revenue of $5.6 million and expanded payer coverage.
The outlook is mixed: analyst consensus is strongly bullish (83% buy ratings), but fundamental risks are high due to persistent losses and cash burn. Upside depends on LYMPHIR's commercial success, while downside risks include funding needs and competitive pressures in oncology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
